1Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, California.
2Department of Neurosurgery, Medical University of Vienna, Austria; and.
J Neurosurg. 2021 Aug 13;136(3):776-785. doi: 10.3171/2021.1.JNS203982. Print 2022 Mar 1.
Given the anatomical complexity and frequently invasive growth of giant pituitary adenomas (GPAs), individually tailored approaches are required. The aim of this study was to assess the treatment strategies and outcomes in a large multicenter series of GPAs in the era of endoscopic transsphenoidal surgery (ETS).
This was a retrospective case-control series of 64 patients with GPAs treated at two tertiary care centers by surgeons with experience in ETS. GPAs were defined by a maximum diameter of ≥ 4 cm and a volume of ≥ 10 cm3 on preoperative isovoxel contrast-enhanced MRI.
The primary operation was ETS in all cases. Overall gross-total resection rates were 64% in round GPAs, 46% in dumbbell-shaped GPAs, and 8% in multilobular GPAs (p < 0.001). Postoperative outcomes were further stratified into two groups based on extent of resection: group A (gross-total resection or partial resection with intracavernous remnant; 21/64, 33%) and group B (partial resection with intracranial remnant; 43/64, 67%). Growth patterns of GPAs were mostly round (11/14, 79%) in group A and multilobular (33/37, 89%) in group B. In group A, no patients required a second operation, and 2/21 (9%) were treated with adjuvant radiosurgery. In group B, early transcranial reoperation was required in 6/43 (14%) cases due to hemorrhagic transformation of remnants. For the remaining group B patients with remnants, 5/43 (12%) underwent transcranial surgery and 12/43 (28%) underwent delayed second ETS. There were no deaths in this series. Severe complications included stroke (6%), meningitis (6%), hydrocephalus requiring shunting (6%), and loss or distinct worsening of vision (3%). At follow-up (mean 3 years, range 0.5-16 years), stable disease was achieved in 91% of cases.
ETS as a primary treatment modality to relieve mass effect in GPAs and extent of resection are dependent on GPA morphology. The pattern of residual pituitary adenoma guides further treatment strategies, including early transcranial reoperation, delayed endoscopic transsphenoidal/transcranial reoperation, and adjuvant radiosurgery.
鉴于巨大垂体腺瘤 (GPA) 的解剖复杂性和经常侵袭性生长,需要采用个体化的方法。本研究旨在评估内镜经蝶窦手术 (ETS) 时代,在大型多中心 GPA 系列中治疗策略和结果。
这是一项回顾性病例对照研究,纳入了在两家三级护理中心接受 ETS 经验丰富的外科医生治疗的 64 例 GPA 患者。术前等体素对比增强 MRI 显示,GPA 的最大直径≥4cm 和体积≥10cm3 。
所有病例的初次手术均为 ETS。圆形 GPA 的总体大体全切除率为 64%,哑铃形 GPA 为 46%,多叶形 GPA 为 8%(p<0.001)。根据切除范围,术后结果进一步分为两组:A 组(大体全切除或部分切除伴海绵窦内残留;21/64,33%)和 B 组(部分切除伴颅内残留;43/64,67%)。A 组中 GPA 的生长模式主要为圆形(11/14,79%),B 组为多叶形(33/37,89%)。A 组中,无患者需要二次手术,21 例中有 2 例(9%)接受辅助放射外科治疗。B 组中,由于残瘤出血性转化,6/43(14%)例早期需要开颅再手术。对于其余 B 组有残瘤的患者,5/43(12%)行开颅手术,12/43(28%)行延迟性第二次 ETS。该系列中无死亡病例。严重并发症包括中风(6%)、脑膜炎(6%)、需要分流的脑积水(6%)和视力丧失或明显恶化(3%)。在随访(平均 3 年,范围 0.5-16 年)中,91%的病例病情稳定。
ETS 作为缓解 GPA 肿块效应的主要治疗方法,其切除范围取决于 GPA 的形态。残余垂体腺瘤的模式指导进一步的治疗策略,包括早期开颅再手术、延迟性内镜经蝶窦/经颅再手术和辅助放射外科治疗。